Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

New advances may slow tumor growth in pancreatic cancer

13.06.2005


Making new strides in their ongoing effort to understand mechanisms behind the relentless growth of cancer cells, researchers at Dartmouth Medical School have found a promising key that may open doors to future treatments in pancreatic and other forms of cancer. The innovation lies in manipulating an overabundance of chemo-resistant molecules in pancreatic cancer that inactivate pathways that would normally suppress cell growth.



Published in the June 10 issue of the Journal of Biological Chemistry, the study was led by Dr. Murray Korc, a pioneer in early research on growth factor receptors in pancreatic cancer, and chair of the department of medicine at Dartmouth Medical School (DMS) and Dartmouth-Hitchcock Medical Center, and a member of the Norris Cotton Cancer Center. His team’s research has focused on suppressing pancreatic tumor growth by determining the mechanisms that enable the cells to grow so quickly.

"Pancreatic cancer is an incredibly resilient and aggressive disease," said Korc. "It grows quickly without causing symptoms, is resistant to chemotherapy, has a strong tendency to metastasize, and patients are often beyond surgery when it is diagnosed."


This study builds on the team’s prior research on a molecule called Smad7, found in half of all human pancreatic cancers. Smad7 lies in pathways that normally play an important role in regulating cell growth and often prevents cells when proliferating too quickly. But Smad7 interferes with these pathways that are normally regulated by TGF-beta molecules, so they cannot regulate the growth of cells, and these cells continue to grow unchecked until they eventually become tumors.

"Previously, we found that Smad7 blocks the ability of TGF-beta to inhibit the growth of these cancer cells," said study co-author Dr. Nichole Boyer Arnold, a postdoctoral fellow at DMS and a member of the Norris Cotton Cancer Center. "In this study, we discovered that Smad7 is able to do this by suppressing the function of the retinoblastoma (RB) protein." The RB protein is crucial to empowering TGF-beta to control cell growth.

DMS researchers also found that pancreatic cancer cells generate TGF-ƒÒ molecules at a much faster rate than normal. "It’s a devilish mechanism," explains Korc. "Smad7 not only prevents TGF-beta molecules from slowing the cancer down, but enables them to multiply at a high rate, and thus gives the cancer another growth benefit. In addition, TGF-beta molecules are still able to stimulate blood vessel formation and enhance the growth of adjoining cells, which further increases the cancer’s ability to metastasize."

Korc likens the process to a scorpion that not only has a newfound immunity to his own poison, but every time he stings himself, he gets bigger and more powerful.

"Now that we know how Smad7 is able to inactivate TGF-beta growth suppressive effects by preventing RB from functioning properly, we can focus our research on the RB protein," said Korc. They hope to find a way to disrupt Smad7’s ability to affect the RB protein in human pancreatic cancers. Of the 31,000 people in the US that get pancreatic cancer this year, 30,300 will die from it, according to Korc, and most patients die within six months, which is why these advances in new therapies are so important.

He notes that even if his lab is able to overcome these problems in RB, it will not lead to a "cure" for pancreatic cancer. Pancreatic patients are under attack from so many different directions that the answer will not lie in one particular aspect of therapy. The authors hope that their work will add to a growing arsenal of treatments that, when combined in a form of therapy individualized to each patient, will have an impact on this devastating disease.

Deborah Kimbell | EurekAlert!
Further information:
http://www.dartmouth.edu

More articles from Studies and Analyses:

nachricht Study relating to materials testing Detecting damages in non-magnetic steel through magnetism
23.07.2018 | Technische Universität Kaiserslautern

nachricht Innovative genetic tests for children with developmental disorders and epilepsy
11.07.2018 | Christian-Albrechts-Universität zu Kiel

All articles from Studies and Analyses >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Color effects from transparent 3D-printed nanostructures

New design tool automatically creates nanostructure 3D-print templates for user-given colors
Scientists present work at prestigious SIGGRAPH conference

Most of the objects we see are colored by pigments, but using pigments has disadvantages: such colors can fade, industrial pigments are often toxic, and...

Im Focus: Unraveling the nature of 'whistlers' from space in the lab

A new study sheds light on how ultralow frequency radio waves and plasmas interact

Scientists at the University of California, Los Angeles present new research on a curious cosmic phenomenon known as "whistlers" -- very low frequency packets...

Im Focus: New interactive machine learning tool makes car designs more aerodynamic

Scientists develop first tool to use machine learning methods to compute flow around interactively designable 3D objects. Tool will be presented at this year’s prestigious SIGGRAPH conference.

When engineers or designers want to test the aerodynamic properties of the newly designed shape of a car, airplane, or other object, they would normally model...

Im Focus: Robots as 'pump attendants': TU Graz develops robot-controlled rapid charging system for e-vehicles

Researchers from TU Graz and their industry partners have unveiled a world first: the prototype of a robot-controlled, high-speed combined charging system (CCS) for electric vehicles that enables series charging of cars in various parking positions.

Global demand for electric vehicles is forecast to rise sharply: by 2025, the number of new vehicle registrations is expected to reach 25 million per year....

Im Focus: The “TRiC” to folding actin

Proteins must be folded correctly to fulfill their molecular functions in cells. Molecular assistants called chaperones help proteins exploit their inbuilt folding potential and reach the correct three-dimensional structure. Researchers at the Max Planck Institute of Biochemistry (MPIB) have demonstrated that actin, the most abundant protein in higher developed cells, does not have the inbuilt potential to fold and instead requires special assistance to fold into its active state. The chaperone TRiC uses a previously undescribed mechanism to perform actin folding. The study was recently published in the journal Cell.

Actin is the most abundant protein in highly developed cells and has diverse functions in processes like cell stabilization, cell division and muscle...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

LaserForum 2018 deals with 3D production of components

17.08.2018 | Event News

Within reach of the Universe

08.08.2018 | Event News

A journey through the history of microscopy – new exhibition opens at the MDC

27.07.2018 | Event News

 
Latest News

Smallest transistor worldwide switches current with a single atom in solid electrolyte

17.08.2018 | Physics and Astronomy

Robots as Tools and Partners in Rehabilitation

17.08.2018 | Information Technology

Climate Impact Research in Hannover: Small Plants against Large Waves

17.08.2018 | Life Sciences

VideoLinks
Science & Research
Overview of more VideoLinks >>>